Novavax (NVAX) FCF Margin (2010 - 2026)
Novavax (NVAX) recorded quarterly FCF Margin of 24.13% in Q1 2026, up 9.47% quarter-over-quarter from 26.66% in Q4 2025, and up 393.0% on a YoY basis from 4.9% in Q1 2025.
Novavax (NVAX) FCF Margin (2010 - 2026) Analysis & Trends
Novavax's FCF Margin history runs 17 years deep, the most recent figure standing at 24.13% for Q1 2026.
- In Q1 2026, FCF Margin rose 393.0% year-over-year to 24.13%; the TTM figure through Mar 2026 stood at 17.14% (down 236.0% YoY), while the FY2025 annual figure was 21.77%, down 875.0% from the prior year.
- FCF Margin was 24.13% for Q1 2026 at Novavax, up from 26.66% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 154.76% in Q3 2025 to a low of 426.67% in Q1 2023.
- Historically, FCF Margin has averaged 63.37% across 5 years, with a median of 36.54% in 2022.
- The sharpest annual moves came in 2023 and 2025: FCF Margin plunged 41171 bps in 2023, then jumped 33854 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 36.54% in 2022, then slumped by 69 bps to 61.58% in 2023, then plunged by 201 bps to 185.28% in 2024, then soared by 86 bps to 26.66% in 2025, then increased by 9 bps to 24.13% in 2026.
- The last three FCF Margin figures came in at 24.13% (Q1 2026), 26.66% (Q4 2025), and 154.76% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Novavax | 1.49 Bn | 931.98 Mn | 108.82 Mn | -24.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.13% |
| Dec 31, 2025 | -26.66% |
| Sep 30, 2025 | 154.76% |
| Jun 30, 2025 | -72.76% |
| Mar 31, 2025 | -28.07% |
| Dec 31, 2024 | -185.28% |
| Sep 30, 2024 | -183.78% |
| Jun 30, 2024 | 77.14% |
| Mar 31, 2024 | -96.35% |
| Dec 31, 2023 | -61.58% |
| Sep 30, 2023 | -18.96% |
| Jun 30, 2023 | -37.40% |
| Mar 31, 2023 | -426.67% |
| Dec 31, 2022 | -36.54% |
| Sep 30, 2022 | -3.50% |
| Jun 30, 2022 | -92.49% |
| Mar 31, 2022 | -14.96% |
| Dec 31, 2021 | -155.44% |
| Sep 30, 2021 | -73.31% |
| Jun 30, 2021 | 49.38% |